Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Skelin

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Neoplasma|September 13, 2024
Artificial immortalization, number of therapy lines, and survival of patients with advanced gastric and esophagogastric adenocarcinomaIvan Krečak, Marko Skelin, Marko Lucijanić
JAMA Cardiology|January 2, 2025
Sex Differences in the Effectiveness and Safety of AspirinMarko Lucijanic, Eugen Javor, Marko Skelin
The New England Journal of Medicine|February 24, 2021
Colchicine in Patients with Chronic Coronary DiseaseMarko Lucijanic, Eugen Javor, Marko Skelin
The New England Journal of Medicine|August 18, 2021
Aspirin Dosing in Cardiovascular DiseaseEugen Javor, Marko Skelin, Marko Lucijanić
Seminars in Oncology Nursing|December 19, 2025
Development of Digital Literacy: Application of Artificial Intelligence in Education and Clinical Practice of Oncology NursesNevena Šimunić, Nikolina Višnjić Junaković, Marko Skelin
International Journal of Cardiology|June 8, 2020
On interactions between body mass index, type of anticoagulation and outcomesMarko Lucijanic, Marko Skelin, Ivana Jurin, et al.
Diabetes Care|January 22, 2020
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920Marko Skelin, Dario Rahelić, Petar Skelin, et al.
Biomedicines|May 27, 2023
Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative NeoplasmsIvan Krečak, Ljerka Pivac, Marko Lucijanić, et al.
Annals of Medicine|August 19, 2016
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitorsDario Rahelić, Eugen Javor, Tomo Lucijanić, et al.
International Journal of Clinical Practice|September 13, 2021
The economic impact of a clinical pharmacist's involvement in the hospital medicines policy in a rural areaEugen Javor, Ali Allouch, Josipa Osvaldić Galic, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Neoplasma|September 13, 2024
Artificial immortalization, number of therapy lines, and survival of patients with advanced gastric and esophagogastric adenocarcinomaIvan Krečak, Marko Skelin, Marko Lucijanić
JAMA Cardiology|January 2, 2025
Sex Differences in the Effectiveness and Safety of AspirinMarko Lucijanic, Eugen Javor, Marko Skelin
The New England Journal of Medicine|February 24, 2021
Colchicine in Patients with Chronic Coronary DiseaseMarko Lucijanic, Eugen Javor, Marko Skelin
The New England Journal of Medicine|August 18, 2021
Aspirin Dosing in Cardiovascular DiseaseEugen Javor, Marko Skelin, Marko Lucijanić
Seminars in Oncology Nursing|December 19, 2025
Development of Digital Literacy: Application of Artificial Intelligence in Education and Clinical Practice of Oncology NursesNevena Šimunić, Nikolina Višnjić Junaković, Marko Skelin
International Journal of Cardiology|June 8, 2020
On interactions between body mass index, type of anticoagulation and outcomesMarko Lucijanic, Marko Skelin, Ivana Jurin, et al.
Diabetes Care|January 22, 2020
Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920Marko Skelin, Dario Rahelić, Petar Skelin, et al.
Biomedicines|May 27, 2023
Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative NeoplasmsIvan Krečak, Ljerka Pivac, Marko Lucijanić, et al.
Annals of Medicine|August 19, 2016
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitorsDario Rahelić, Eugen Javor, Tomo Lucijanić, et al.
International Journal of Clinical Practice|September 13, 2021
The economic impact of a clinical pharmacist's involvement in the hospital medicines policy in a rural areaEugen Javor, Ali Allouch, Josipa Osvaldić Galic, et al.
Pageof 7